Can a High Reloading Dose of Atorvastatin Prior to Percutaneous Coronary Intervention Reduce Periprocedural Myocardial Infarction?

References

• Cavallini C, Savonitto S, Violini R, et al. Impact of the elevation of biochemical markers of myocardial damage on long-term mortality after percutaneous coronary intervention: results of the CK-MB and PCI study. Eur Heart J 2005;26:1494-8
   PubMed Web of Science ®Google Scholar
• Babu GG, Walker JM, Yellon DM, et al. Peri-procedural myocardial injury during percutaneous coronary intervention: an important target for cardioprotection. Eur Heart J 2011;32:23-31
   PubMed Web of Science ®Google Scholar
• Thygesen K, Alpert JS, White HD. Universal definition of myocardial infarction. Eur Heart J 2007;28:2525-38
   PubMed Web of Science ®Google Scholar
• Ioannidis JP, Karvouni E, Katritsis DG. Mortality risk conferred by small elevations of creatine kinase-MB isoenzyme after percutaneous coronary intervention. J Am Coll Cardiol 2003;42:1406-11
   PubMed Web of Science ®Google Scholar
• Simoons ML, van den Brand M, Lincoff M, et al. Minimal myocardial damage during coronary intervention is associated with impaired outcome. Eur Heart J 1999;20:1112-19
   PubMed Web of Science ®Google Scholar
• Rosenson RS, Tangney CC. Antiatherothrombotic properties of statins – implications for cardiovascular event reduction. JAMA 1998;279:1643-50
   PubMed Web of Science ®Google Scholar
• Sposito AC, Chapman MJ. Statin therapy in acute coronary syndromes: mechanistic insight into clinical benefit. Arterioscler Thromb Vasc Biol 2002;22:1524-34
   PubMed Web of Science ®Google Scholar
• Patti G, Pasceri V, Colonna G, et al. Atorvastatin pretreatment improves outcomes in patients with acute coronary syndromes undergoing early percutaneous coronary intervention: results of the ARMYDA-ACS randomized trial. J Am Coll Cardiol 2007;49:1272-8
   PubMed Web of Science ®Google Scholar
• Yun KH, Jeong MH, Oh SK, et al. The beneficial effect of high loading dose of rosuvastatin before percutaneous coronary intervention in patients with acute coronary syndrome. Int J Cardiol 2009;137:246-51
   PubMed Web of Science ®Google Scholar
• Scuffham PA, Kósa J. The cost-effectiveness of fluvastatin in Hungary following successful percutaneous coronary intervention. Cardiovasc Drugs Ther 2006;20:309-17
   PubMed Web of Science ®Google Scholar
• Briguori C, Colombo A, Airoldi F, et al. Statin administration before percutaneous coronary intervention: impact on periprocedural myocardial infarction. Eur Heart J 2004;25:1822-8
   PubMed Web of Science ®Google Scholar
• Pasceri V, Patti G, Nusca A, et al. Randomized trial of atorvastatin for reduction of myocardial damage during coronary intervention: results from the ARMYDA (Atorvastatin for Reduction of MYocardial Damage during Angioplasty) study. Circulation 2004;110:674-8
   PubMed Web of Science ®Google Scholar
• Briguori C, Visconti G, Focaccio A, et al. Novel Approaches for Preventing or Limiting Events (NAPLES) II trial impact of a single high loading dose of atorvastatin on periprocedural myocardial infarction. J Am Coll Cardiol 2009;54:2157-63
   PubMed Web of Science ®Google Scholar
• Di Sciascio G, Patti G, Pasceri V, et al. Efficacy of atorvastatin reload in patients on chronic statin therapy undergoing percutaneous coronary intervention. Results of the ARMYDA-RECAPTURE (Atorvastatin for Reduction of Myocardial Damage During Angioplasty) randomized trial. J Am Coll Cardiol 2009;54:558-65
   PubMed Web of Science ®Google Scholar
• Smith SC, Feldman TE, Hirshfeld JW, et al. ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to Update the 2001 Guidelines for Percutaneous Coronary Intervention). J Am Coll Cardiol 2006;47:e1-121
   PubMed Web of Science ®Google Scholar
• King SB, Smith SC, Hirshfeld JW, et al. 2007 focused update of the ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines: 2007 Writing Group to review new evidence and update the ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention, writing on behalf of the 2005 Writing Committee. Circulation 2008;117:261-95
   PubMed Web of Science ®Google Scholar
• Kushner FG, Hand M, Smith SC, et al. 2009 focused updates: ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction (updating the 2004 guideline and 2007 focused update) and ACC/AHA/SCAI guidelines on percutaneous coronary intervention (updating the 2005 guideline and 2007 focused update) a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2009;54:2205-41
   PubMed Web of Science ®Google Scholar
• Thygesen K, Alpert JS, Jaffe AS, et al. Third universal definition of myocardial infarction. J Am Coll Cardiol 2012;60:1581-98
   PubMed Web of Science ®Google Scholar
• Sun Y, Qi G, Gao Y, et al. Effect of different loading doses of atorvastatin on percutaneous coronary intervention for acute coronary syndromes. Can J Cardiol 2010;26:481-5
   PubMed Web of Science ®Google Scholar
• Zhang M, Que B, Nie SP, et al. The effect of pre-hospital statins therapy on incidence of in-hospital death and total MACCE in patients with PCI. J Clin Pharmacy Therapeut 2008;33:613-17
   PubMed Web of Science ®Google Scholar
• Winchester DE, Wen X, Xie L, et al. Evidence of pre-procedural statin therapy. A meta-analysis of randomized trials. J Am Coll Cardiol 2010;56:1099-109
   PubMed Web of Science ®Google Scholar
• Li X, Yang Y, Hao Y, et al. Effect of pre-procedural statin therapy on myocardial no-reflow following percutaneous coronary intervention: a meta analysis. Chinese Med J 2013;126:1755-60
   PubMed Web of Science ®Google Scholar
• Chyrchel M, Rakowski T, Rzeszutko L, et al. Effects of high-dose statin administered prior to coronary angioplasty on the incidence of cardiac events in patients with acute coronary syndrome. Kardiologia polska 2006;64:1357
   PubMedGoogle Scholar
• Davignon J. Beneficial cardiovascular pleiotropic effects of statins. Circulation 2004;109:III-39-43
   Web of Science ®Google Scholar
• Sang KHLQ, Levenson J, Megnien JL, et al. Platelet cytosolic Ca2+ and membrane dynamics in patients with primary hypercholesterolemia: effects of pravastatin. Arterioscler Thromb Vasc Biol 1995;15:759-64
   PubMed Web of Science ®Google Scholar
• Ludman A, Venugopal V, Yellon DM, et al. Statins and cardioprotection – more than just lipid lowering? Pharmacol Therapeut 2009;122:30-43
   PubMed Web of Science ®Google Scholar
• Bourcier T, Libby P. HMG CoA reductase inhibitors reduce plasminogen activator inhibitor-1 expression by human vascular smooth muscle and endothelial cells. Arterioscler Thromb Vasc Biol 2000;20:556-62
   PubMed Web of Science ®Google Scholar
• Osamah H, Mira R, Sorina S, et al. Reduced platelet aggregation after fluvastatin therapy is associated with altered platelet lipid composition and drug binding to the platelets. Br J Clin Pharmacol 1997;44:77-84
   PubMed Web of Science ®Google Scholar
• Nesar HV, Yosef NK, Abdollahian F. Short-term therapy with high dose atorvastatin in patients with coronary artery disease can reduce inflammatory process. Acta Medica Iranica 2010;48:218
   PubMedGoogle Scholar
• Sun Y, Ji Q, Mei Y, et al. Role of preoperative atorvastatin administration in protection against postoperative atrial fibrillation following conventional coronary artery bypass grafting. Int Heart J 2011;52:7-11
   PubMed Web of Science ®Google Scholar
• Kuklinska AM, Mroczko B, Musial WJ, et al. Hypotensive effect of atorvastatin is not related to changes in inflammation and oxidative stress. Pharmacol Rep 2010;62:883-90
   PubMed Web of Science ®Google Scholar
• Puccetti L, Santilli F, Pasqui AL, et al. Effects of atorvastatin and rosuvastatin on thromboxane-dependent platelet activation and oxidative stress in hypercholesterolemia. Atherosclerosis 2011;214:122-8
   PubMed Web of Science ®Google Scholar